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Abstract: The hydroxy-pyrazole and 3-hydroxy-oxindole motifs have been utilised in several pharma
and agrochemical leads but are distinctly underrepresented in the scientific literature due to the
limited routes of preparation. We have developed a one-pot procedure for their synthesis starting
from simple isatins. The method employs cheap and easy-to-handle building blocks and allows
easy isolation.
Keywords: pyrazole; oxindole; isatin; Pfitzinger reaction; Knorr pyrazole synthesis; quinoline;
15N-MASNMR
1. Introduction
The pyrazole moiety is commonly found in several pharmaceuticals and agrochemicals [1].
In particular, hydroxy-pyrazole units are described as antiviral (HIV-1 non-nucleoside reverse
transcriptase inhibitors, 1) [2], anti-diabetic (Na-glucose cotransporter inhibitors, 3) [3–5], anti-cancer
(Hsp90 inhibitor, 2) [6], anti-thrombotic (P2Y1 antagonist 4) [7], and antibacterial agents (5) [8,9]
(examples in Figure 1).
Figure 1. Examples of hydroxy-pyrazole derivatives described in literature.
The 3-hydroxy-2-oxindole moiety is another related and widely represented motif present in
several natural products (9,10,12) [10–14]. This scaffold has recently been employed in several areas
of pharmacology (examples in Figure 2), and it has been described in the context of anti-cancer
(tryptophan 2,3-dioxygenase inhibitor, 6) [15], anticonvulsant (8) [16], cytotoxic (11) [17] and growth
hormone releasing agents (i.e., SM-130686, 7) [18,19].
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Figure 2. Examples of 3-hydroxy-2-oxindoles derivatives described in literature.
Several methodologies for the generation of oxindole systems have been reported with one of
these employing isatin [20]. Isatin (13) is an endogenous compound whose structure appears many
times in natural products which have wide-ranging pharmacological activities. It has thus been widely
utilised as a starting material in the preparations of a range of drug candidates [21].
Our research aim was to devise and validate a simple preparation comprising of the above cited
pharmacophores, 3-hydroxy-pyrazole and 3-hydroxy-2-oxindole, based upon presenting the cores in a
unique 3D architecture which could be easily tailored to further any medicinal chemistry exploration.
To the best of our knowledge, structures such as compound 15 have not previously been made, and
therefore, it would be of great interest for exploring these new areas of chemical space (Scheme 1).
Scheme 1. Proposed retrosynthetic synthesis of compound 15 starting from isatin (13).
2. Results and Discussion
2.1. Optimisation of the Synthesis Method
To achieve this aim we first investigated a base-catalysed aldol reaction as described by
Liu et al. [22]. We decided to screen different reaction conditions, including evaluation of bases,
in order to optimise the reaction for isatin 13 (Scheme 2 and Table 1).
Scheme 2. General conditions applied for the preparation of 14.
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Table 1. Screening of different bases for the synthesis of 14.
Entry a Base (10 mol%) Solvent Conversion (%) b Yield (%) c
1 Triethylamine MeOH 38 36
2 DBU MeOH 13 0
3d DBU THF 88 46
4 Pyrrolidine MeOH 92 84
5 K2CO3 MeOH 77 26
6 Morpholine MeOH 36 36
7 N,N-diethylethylendiamine MeOH 55 33
8 Piperidine MeOH 93 87
9e Piperidine MeOH - -
10 Piperidine iPrOH 96 84
11 Piperidine H2O 53 15
12 Piperidine MeCN 87 59
13 Piperidine THF 90 67
14 Piperidine Toluene 61 27
15 Piperidine AcOEt 84 81
a The experiments were carried out at 1 mmol scale; b Detected conversions based on 1H-Nuclear Magnetic Resonance
(1H-NMR) spectra; c Isolated yield following chromatography; d Note the original literature [23] used 5 equiv. of
methyl acetoacetate; e The reaction mixture was at 65 ◦C for 2 h and a complex mixture was obtained, no further
analysis was performed.
Piperidine was found to be the most effective catalyst allowing the desired compound to be
obtained in 87% isolated yield (Entry 8). Whilst pursuing this work, Zhang et al. [23] reported the use
of 1,8-diazabicyclo(5.4.0)undece-7-ene (DBU) in tetrahydrofuran (THF) as the preferred solvent for
such a reaction. We had previously attempted to use DBU in MeOH, which had been disappointing
(Entry 2). Unfortunately, changing the solvent to THF, although consuming the isatin, generated
the desired product in only a modest 46% isolated yield (Entry 3). The by-products were difficult
to isolate and were found unstable. Therefore, progressing with our catalyst of choice, piperidine,
we investigated an expanded range of solvents. Additionally, inspired by the effect of water on
1,6-Michael additions as described by Kashinath et al., we also investigated water. However, for
this reaction only a 15% conversion was detected, probably due to the low solubility of the starting
materials in the aqueous media (Entry 11) [24]. No mixture with water was screened. Overall, MeOH
still remained the best solvent; nonetheless, less polar solvents such as AcOEt and iPrOH also gave
promising results (Entries 10 and 15). Attempts to avoid chromatography, by isolating and purifying
the product by recrystallization, failed. Having determined effective conditions for the preparation of
intermediate 14, we next examined the pyrazole formation using different hydrazine sources starting
with hydrazine monohydrate.
To facilitate the transformation, intermediate 14 was mixed with excess hydrazine monohydrate
and stirred at ambient temperature (Scheme 3). After 4 days, a precipitate was formed, which was
isolated and identified as the quinoline 16, which is formed via a Pfitzinger type reaction [25,26],
occurring via either water or hydrazine attack on the position 2 of the oxindole intermediate 14 (green
route, Scheme 3).
From this initial result we also investigated other hydrazine sources (Table 2). As our ultimate
challenge was to develop a one-pot process, we examined the second step as a telescoped transformation
of 13 to 15. Although the THF solution of hydrazine gave good results (Entry 3), we elected for safety
considerations to keep using hydrazine monohydrate, as it is more stable, much cheaper and more
widely available [27]. The better outcomes obtained from the hydrazine solution may be attributable
to a dilution effect as diluted hydrazine is added in the mixture.
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Scheme 3. Initial reaction conditions employed for the preparation of 15. When hydrazine attacks the
carbonyl, the pyrazole 15 is formed (Knorr synthesis), whereas the addition of water or hydrazine into
the amide group (marked position 2) triggers the Pfitzinger reaction. The X-ray structure of product 16
is shown in the bottom right of the picture.
Table 2. Screening of different hydrazine sources for the synthesis of the pyrazole 15.
Molecules 2020, 25, x FOR PEER REVIEW 4 of 14 
 
Scheme 3. Initial reaction conditions employed for the preparation of 15. When hydrazine attacks 
the carbonyl, the pyrazole 15 is formed (Knorr synthesis), whereas the addition of water or 
hydrazine into the amide group (marked position 2) triggers the Pfitzinger reaction. The X-ray 
structure of product 16 is shown in the bottom right of the picture. 
From this initial result we also investigated other hydrazine sources (Table 2). As our ultimate 
challenge was to develop a one-pot process, we examined the second step as a telescoped 
transformation of 13 to 15. Although the THF solution of hydrazine gave good results (Entry 3), we 
elected for safety considerati s t  keep using hydrazine monohydrate, as it is more stable, much 
cheaper a d more widely available.[27] The better outcomes obtained from the hydrazi  solution 
may b  ttributable to  dilution effec  as diluted hydrazin  is added in the mix e. 
Table 2. Screening of different hydrazine sources for the synthesis of the pyrazole 15. 
 
Entry a Reagent b Conv. 15 (%) c Conv. 16 (%) c 
1 NH2NH2 ∙H2O 21  36 
2 NH2NH2 ∙HCl 20 20 
3d NH2NH2 53 42 
a The experiments were carried out on 5 mmol scale; b 4 equivalents of reagent were used; c detected 
conversion based on 1H-NMR spectra; d A 1 M THF solution was employed. 
As Table 3 shows, the conversion to the oxindole 15 increased, and the quantity of quinoline 16 
halved when the mixture was only reacted for 2 h (Entry 2). We later discovered that compound 15 
completely decomposed after 10 days under the reaction conditions, whereas compound 16 was 
stable. We showed that the formation of compound 15 is partially reversible under the reaction 
conditions (15→14), and it cannot be attributed to the solvent. Consequently, compound 16 acts as a 
thermodynamic sink, and over time, its proportion increases in the reaction mixture. Overall, our 
best results were obtained when the hydrazine was slowly added to the mixture, with the desired 
material 15 being isolated via reverse-phase column chromatography in 38% yield (Table 3, entry 3). 
  
Entry a Reagent b Conv. 15 (%) c Conv. 16 (%) c
1 NH2NH2 ·H2O 21 36
2 NH2NH2 ·HCl 20 20
3d NH2NH2 53 42
a The xperiments were carried out on 5 mmol scale; b 4 equivalents of reagent w re used; c detected conversion
based on 1H-NMR spectra; d A 1 M THF solution was employed.
As Table 3 shows, the conversion to the oxindole 15 increased, and th quantity f quinoline
16 halved wh n the mixture was onl reacted for 2 h (Entry 2). We later discovered that compound
15 completely decomposed after 10 days under the reaction conditions, whereas compound 16 was
stable. We showed that the formation of comp und 15 is partially reversible under the reaction
conditions (15→14), and it cannot b attributed to the solvent. Cons quently, compound 16 acts as a
thermodynamic sink, d over time, its proportion increases in th reaction i t r . Overall, our best
results were obtained when the hydrazine was slowly added t the mixture, with the desired material
15 being isolated via reverse-phase column chromatography in 38% yield (Table 3, entry 3).
Table 3. Optimisation of the reaction conditions for the preparation of the pyrazole 15.
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Entry a Reaction Time (h) Hydrazine Addition Conv. 15 (%) b Conv. 16 (%) b
1 96 fast 21 36
2 2 fast 28 17
3 2 dropwise c 50 (38) 16 (15)
4d 2 dropwise 43 11
5e 2 dropwise 53 10
a The experiments were carried out on 5 mmol scale; b detected conversions based on 1H-NMR spectra; c the
hydrazine was added over 15 min; d addition performed at −78 °C. Isolated yields in parentheses; e the hydrazine
monohydrate was added as a 1 M solution in MeOH.
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Having established a set of optimised conditions, we decided to screen other isatin derivatives
and examine the different reactivity (Table 4). Despite optimisation, the purification step of the
compounds 15a–j and 16a–j remained challenging in some cases. Consequently, we managed to isolate
the compounds 15a–j, but not all of the corresponding quinoline 16 derivatives could be isolated
cleanly. Attempts of crystallisations with different solvents (MeOH, EtOH, iPrOH, H2O, Et2O, THF,
Toluene) brought about sticky materials as they incorporate solvent. The 5-, 6- and 7-chloro derivatives
(respectively, 15d, 15g and 15h) were isolated in slightly better yields compared to 15 (Entries 4, 7 and
8). However, the highest conversions of 16 are detected when the 5-chloro and 5-fluoro substrates are
used, attributed to the electronic effect of an electro-withdrawing group in para to the amide. This is
consistent with the fact that an electro-donating group such as a methoxy in the 5-position reduces
the quinoline formation (Entry 5). A similar electronic effect is also noticed when the chlorine is in
the position 7, although the fluorine and the bulkier trifluoromethyl group do still form traces of the
quinoline (Entries 8–10).
Table 4. Application of the optimised conditions for the synthesis of the derivatives 15a–j.
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1 4-F a 13 (10) 9 (- c)
2 4-Cl b 92 (81) 0
3 4-Br c 93 (91) 0
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5 5-MeO e 45 (41) - c (11)
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When 4-fluoroisatin (13a) was exploited in the reparation metho (Entry 1), the r action occurred
in very low conversions (only 30% of the isatin reacts). This outcome is attributed to the low
electrophilicity of the isatin ketone which hampers the first step from occurring. This hypothesis
is supported up by the 13C chemical shift of the carbonyl acquired in solid state (13C δ 179.15 ppm)
compared with isatin 13 (13C δ 184.39 ppm), and a resultant higher stretching frequency of the same
carbonyl (1739 cm−1 vs. 1721 cm−1) in Fourier transform infrared (FT-IR) spectra (see supporting
materials). Indeed, substrate 13a shows only poor conversion to the corresponding aldol adduct 14a.
To our delight, when other halogens in position 4 were tested, the pyrazoles (15b–c) were isolated
in high yields (Entries 2 and 3). We suggested a Thorpe–Ingold type effect due to the bulk of the halogen
group, which lowers the ring opening of the oxindole ring and accelerates the pyrazole cyclization.
This could be confirmed by the raise in conversions with increasing halogen size (from chloro to
bromo). Compound 15c was crystallized and the structure of the crystal was resolved (Figure 3).
In an attempt to reduce the competitive quinoline formation (compound 16) by making the
nitrogen a worse leaving group, we N-benzyl-protected the nitrogen (Scheme 4). To our delight, the
corresponding compound 15l was isolated in a superior yield (79%). This compound was also highly
crystalline, and an X-ray structure was also obtained to validate the molecular connectivity.
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Figure 3. X-ray structure of the compound 15c where the pyrazole is in its keto form.
Scheme 4. Methodology applied to the N-benzyl-protected isatin 13l. The X-ray structure of 15l is also
pictured, where the pyrazole is in its enol form.
2.2. Observations of the Spectroscopic Data Obtained Illustrated for Compound 15
In order to confirm the structure of the molecules obtained, we exploited different spectroscopic
methodologies. Recorded solution-state Nuclear Magnetic Resonance (NMR) spectra confirm the
presence of two diastereotopic protons (δ 3.03 and 2.88 ppm) that by 2D NMR correlate with carbons
present on the 2-oxindole group and on the pyrazole. The signals regarding the 3-hydoxypyrazole (13C
δ 160.46, 138.04, 88.86 ppm) match those obtained from similar scaffolds by Ayoub et al. in 1981 [28].
In their report, the authors noticed a proton exchange process occurs in solution which involves the
pyrazole’s protons and all the other labile protons present in the molecule. Solution-state 15N-NMR
heteronuclear single quantum coherence (HSQC) and heteronuclear multiple bond coherence (HMBC)
spectra were acquired and allowed the assignment of the 15N chemical shift of N1; however, due to
the fast proton exchange, the experiments were unable to identify the other two nitrogen. N14 and
N15 (15N δ −198, −215 ppm) were instead identified, along with the N1 (−248 ppm), when solid-state
15N- magic angle spinning NMR (15N-MASNMR) spectra were acquired. Furthermore, suppression of
both the N14 and N15 signals in a cross-polarisation polarisation-inversion (CPPI) experiment is an
indication of a proton exchange process occurring in the solid state (Figure 4).
Figure 4. Structure of the desired material 15 and its 15N- cross polarisation (CP) (top) and cross-
polarisation polarisation-inversion (CPPI) (bottom) MASNMR spectra.
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Unfortunately, all attempts to generate crystals of compound 15 produced amorphous powders.
However, to our delight, we managed to crystallise certain derivatives of 15 and confirm the structures
of the analogous products (e.g., 15c, 15l, Figure 5). In the solid state, the molecules 15 form closely
packed lattices with extensive H-bonding interaction which would account for the ease of the proton
exchange identified in the 15N-MASNMR analysis.
Figure 5. Pictures showing the packaging in the crystal structure of 15l (left side) and 15c (right side).
The H-bonding interactions between the molecules can be noticed (N2/N3 = N15/14).
3. Materials and Methods
Unless otherwise stated, all solvents were purchased from Fisher Scientific (Loughborough,
Leicestershire, UK) and used without further purification. Substrates, their precursors and reagents
were purchased from Alfa Aesar (Haverhill, MA, USA), Sigma Aldrich (Merck KGaA, Darmstadt,
Germany), Fluorochem (Hadfield, Derbyshire, United Kingdom) or TCI (Tokyo, Tokyo, Japan).
1H-NMR spectra were recorded on either Bruker Avance-400, Varian VNMRS-700 or Varian
VNMRS-500 instruments (Bruker UK Limited, Coventry, UK) and are reported relative to residual
solvent DMSO-d6 (δ 2.50 ppm). 13C-NMR spectra were recorded on the same instruments and are
reported relative to DMSO-d6 (δ 39.52 ppm). Data for 1H-NMR are reported as follows: chemical shift
(δ/ppm) (multiplicity, coupling constant (Hz), integration). Multiplicities are reported as follows: s
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad signal. Data for 13C-NMR
are reported in terms of chemical shift (δC/ppm). DEPT-135, COSY, HSQC, HMBC, PSYCHE and
NOESY experiments were used in structural assignments. Solid-state NMR experimental information
is included in the Supplementary Information. Single crystals X-ray diffraction experiments were
carried out on a Bruker D8 Venture diffractometer with PHOTON 100 CMOS area detector (Bruker UK
Limited, Coventry, UK), using Mo-Kα (15c, 15l) or Cu-Kα (16) radiation from Incoatec IµS microsources
with focusing mirrors. The crystals were cooled using a Cryostream 700 (Oxford Cryosystems, (Oxford,
Oxfordshire, UK) open-flow N2 gas cryostat. The structures were solved by dual-space intrinsic
phasing (SHELXT [29] program) and refined by full-matrix least squares using SHELXL [30] software
on Olex2 platform [31].
IR spectra were obtained using a Perkin Elmer Spectrum Two UATR Two FT-IR Spectrometer
(neat, ATR sampling, (Waltham, MA, USA)) with the intensities of the characteristic signals being
reported as weak (w, <20% of tallest signal), medium (m, 21–70% of tallest signal) or strong (s, >71% of
tallest signal).
Low resolution liquid chromatography mass spectrometry (LC-MS) was performed using a Waters
TQD mass spectrometer (Waters Corp., Milford, MA, USA) and an Acquity UPLC BEH C18 1.7 µm
column (2.1 mm × 50 mm) in ESI mode. ESI-HRMS was performed using a Waters QtoF Premier mass
spectrometer (Waters Corp., Milford, MA, USA). For accurate mass measurements the deviation from
the calculated formula is reported in mDa. Melting points were recorded on an Optimelt automated
melting point system with a heating rate of 1 ◦C/min and are uncorrected. All the purifications were
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performed using a Teledyne CombiFlash® Rf+ (Teledyne ISCO, Lincoln, NE, USA) equipped with a
RediSep Rf Gold 150 g high performance C18 cartridge. The purification was performed at a flow of
75 mL/min using a gradient from 15% methanol in water to 60% methanol in water in 20 min. The
cartridge was then washed with 100% methanol and conditioned in 50% methanol in water for storage.
The water from the sample was removed using a Labconco FreeZone 4.5 L freeze dry system (Labconco,
Kansas City, MO, USA) connected with a Leybold Trivac® B D4B rotary cane vacuum pump (Leybold
GmbH, Cologne, Germany). Organic solutions were concentrated under reduced pressure using a
Buchi rotary evaporator and high vacuum was achieved using an Edwards RV5 pump and Schlenk
line (BÜCHI Labortechnik AG, Postfach, Flawil, Switzerland).
3.1. General Procedure for the Synthesis of 14
To a heterogeneous mixture of isatin (735 mg, 5 mmol, 1 eq.) in MeOH (36 mL), was added methyl
acetoacetate (650 µL, 6 mmol, 1.2 eq.) and piperidine (50 µL, 0.5 mmol, 0.1 eq.). The mixture was stirred
at room temperature for 3 days. The solvent was then removed under reduced pressure to furnish 14
as a crude amorphous powder. The residue was purified using flash chromatography (eluent: 2.5%
MeOH in dichloromethane) to isolate a pale orange amorphous solid (87% isolated yield).
3.2. General Procedure for the Synthesis of 15a–j
To a heterogeneous mixture of the appropriate isatin 13a–j (5 mmol, 1 eq.) in MeOH (36 mL), was
added methyl acetoacetate (650 µL, 6 mmol, 1.2 eq.) and piperidine (50 µL, 0.5 mmol, 0.1 eq.). The
mixture was stirred at room temperature for 3 days. Hydrazine monohydrate (970 µL, 20 mmol, 4 eq.)
was added dropwise at room temperature. After stirring the solution for 2 h, the mixture was partly
concentrated in vacuo and Celite® was added before all the solvent was removed. The residue was
purified via reversed-phase chromatography as described above.
3.3. Characterisation of the Compounds 14 and 15a-j and 16 Derivatives
Methyl 4-(3-hydroxy-2-oxoindolin-3-yl)-3-oxobutanoate (14): 1H NMR (700 MHz, DMSO-d6) δ 10.24 (s,
1H), 7.23 (d, J = 7.3 Hz, 1H), 7.18 (td, J = 7.7, 1.3 Hz, 1H), 6.91 (td, J = 7.3, 1.0 Hz, 1H), 6.78 (d, J = 7.7
Hz, 1H), 6.07 (s, 1H), 3.61 (s, 2H), 3.57 (s, 3H), 3.38 – 3.34 (m, 1H, overlapping with H2O), 3.09 (d, J =
17.0 Hz, 1H). 13C NMR (176 MHz, DMSO-d6) δ 200.27, 177.89, 167.36, 142.48, 131.20, 129.09, 123.79,
121.28, 109.48, 72.52, 51.76, 49.49, 49.20. IR (neat): ν (cm−1) = 3264 (OH, br), 2955 (CH, w), 1705 (C=O,
s), 16,121 (CH, m), 1472 (OH, m), 1185 (C-O, m), 1013 (w), 753 (m). LC-MS Rt = 1.18 min m/z [M + H]+
= 264.2; HR-MS calculated for C13H14NO5 264.0872, found 264.0855 (∆ = −1.7 mDa). Melting point
(◦C): 100 ◦C decomposition.
3-Hydroxy-3-[(3-hydroxy-1H-pyrazol-5-yl)methyl]indolin-2-one (15): 1H NMR (700 MHz, DMSO-d6) δ
10.20 (brs, 2H), 7.17 (td, J = 7.7, 1.3 Hz, 1H), 7.11 (dd, J = 7.4, 1.3 Hz, 1H), 6.93 (td, J = 7.5, 1.0 Hz, 1H),
6.73 (d, J = 7.7 Hz, 1H), 4.80 (s, 1H), 3.05 (d, J = 14.0 Hz, 1H), 2.90 (d, J = 14.0 Hz, 1H). 13C NMR (176
MHz, DMSO-d6) δ 178.51, 160.48, 142.01, 138.04, 131.20, 129.12, 124.32, 121.45, 109.48, 88.86, 74.89, 34.38.
15N NMR (71 MHz, DMSO-d6) δ -246.15 (15N-1H HSQC shows correlation with the peak at δ 10.19
ppm in the 1H-NMR). 13C CPMAS MS-NMR (101 MHz) δ 179.98, 162.65, 142.72, 139.51, 132.79, 129.78,
127.43, 123.91, 110.57, 91.77, 76.77, 35.52. 15N CPMAS MS-NMR (40.556 MHz) δ −197.54, −214.53,
−244.66. LC-MS (ESI+) Rt = 0.70 min m/z [M + H]+ = 246.7 HR-MS calculated for C12H12N3O3 246.0879,
found 246.0878 (∆ = −0.1 mDa). IR (neat): ν (cm−1) = 3161 (NH, w), 2966 (CH, w), 1703 (C=O, s), 1595
(C=N, s), 1471 (s), 1340 (w), 1259 (m), 1078 (m), 1043 (s), 778 (w), 748 (w). Melting point (◦C): 188
◦C decomposition.
2-(2-Hydrazinyl-2-oxoethyl)quinoline-4-carbohydrazide (16): 1H NMR (700 MHz, DMSO-d6) δ 9.90 (s, 1H),
9.37 (s, 1H), 8.10 (d, J = 8.4 Hz, 1H), 7.99 (d, J = 8.4 Hz, 1H), 7.78 (t, J = 7.7 Hz, 1H), 7.61 (t, J = 7.6 Hz,
1H), 7.50 (s, 1H), 4.67 (s, 2H), 4.29 (s, 2H), 3.78 (s, 2H). 13C NMR (176 MHz, DMSO-d6) δ 168.5, 166.3,
156.9, 147.8, 141.8, 130.3, 129.2, 127.1, 125.7, 123.7, 120.3, 44.1. IR (neat): ν (cm−1)= 3285 (NH, m), 3176
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(NH, m), 1620 (C=O, s), 1533 (s), 1362 (m), 1174 (w), 1035.9 (w), 1005 (m), 879.4 (m), 758.4 (s), 699.1
(s). LC-MS: Rt= 2.41 min m/z [M + H]+ = 176.6; HR-MS calculated for C12H14N5O2 260.1147, found
260.1136 (∆ = −1.1 mDa). Melting point (◦C): 220 ◦C decomposition. Crystal data: C12H15N5O3·H2O
(M = 277.29 g/mol), monoclinic, space group P21/n (no. 14), a = 4.9407(5) Å, b = 14.0587(13) Å, c =
18.2746(16) Å, β = 97.040(5)◦, V = 1259.8(2) Å3, Z = 4, T = 120 K, µ(Cu-Kα) = 0.91 mm−1, Dcalc = 1.462
g/cm3, 7750 reflections measured (2Θ ≤ 117◦), 1719 unique (Rint = 0.086, Rσ = 0.080), R1 = 0.049 on
1183 data with I > 2σ(I), wR2 = 0.106 on all data, CCDC-1986566.
4-Fluoro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15a): 1H NMR (700 MHz,
DMSO-d6) δ 10.18 (brs, 3H), 7.22 (td, J = 8.1, 5.4 Hz, 1H), 6.73 (t, J = 8.8 Hz, 1H), 6.55 (d, J =
7.7 Hz, 1H), 4.65 (s, 1H), 3.19 (d, J = 14.0 Hz, 1H), 3.08 (d, J = 14.0 Hz, 1H). 13C NMR (176 MHz,
DMSO-d6) δ 177.58, 159.75, 158.35, 144.36 (d, J = 9.6 Hz), 137.71, 131.45 (d, J = 8.5 Hz), 116.53 (d, J
= 19.7 Hz), 109.01 (d, J = 20.6 Hz), 106.03, 87.87, 75.21, 33.30.13C CPMAS NMR (101 MHz) δ 179.99,
163.78, 161.32, 158.58, 143.68, 132.32, 115.96, 108.95, 91.29, 77.24, 34.06. 15N CPMAS NMR (40.556 MHz)
δ −203.58, −221.81, −243.52. LC-MS (ESI+) Rt = 0.80 min m/z [M+H]+ = 264.2. HR-MS calculated for
C12H11N3O3F 264.0784, found 264.0766 (∆ = −1.8 mDa). IR (neat): ν (cm−1) = 3103 (NH, w), 2748 (CH,
w), 1709 (C=O, s), 1638 (C=N, s), 1567 (s), 1493 (m), 1464 (s), 1256 (w), 1229 (m), 1053 (m), 1033 (w),
1005 (w), 765 (s), 682 (w). Melting point (◦C): 100 ◦C decomposition.
4-Chloro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15b): 1H NMR (599 MHz,
DMSO-d6) δ 10.32 (brs, 3H), 7.20 (t, J = 8.0 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.67 (d, J = 7.8 Hz,
1H), 6.27 (s, 1H), 4.55 (s, 1H), 3.47 (d, J = 14.0 Hz, 1H), 3.05 (d, J = 14.0 Hz, 1H). 13C NMR (151 MHz,
DMSO-d6) δ 177.46, 160.57, 144.34, 137.42, 130.90, 130.54, 127.14, 122.35, 108.44, 87.63, 76.14, 32.08. 13C
CPMAS NMR (101 MHz) δ 179.71, 164.07, 144.60, 134.63, 129.32, 123.84, 110.28, 92.38, 77.59, 33.72. 15N
CPMAS NMR (40.556 MHz) δ −217.29, −224.15, −241.86. LC-MS (ESI+) Rt = 1.35 min m/z [M + H]+ =
280.5 HR-MS calculated for C12H11N3O3Cl 280.0489, found 280.0485 (∆= 0.4 mDa). IR (neat): ν (cm−1)
= 3074 (NH, w), 2703 (CH, w), 1713 (C=O, s), 1589 (C=N, s), 1449 (s), 1415 (m), 1175 (m), 1083 (m), 948
(w), 765 (s), 657 (w). Melting point (◦C): 135 ◦C decomposition.
4-Bromo-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15c): 1H NMR (700 MHz,
DMSO-d6) δ 10.32 (brs, 3H), 7.19 – 7.03 (m, 2H), 6.70 (dd, J = 6.6, 2.1 Hz, 1H), 6.24 (s, 1H), 4.51
(s, 1H), 3.56 (d, J = 14.0 Hz, 1H), 3.01 (d, J = 14.0 Hz, 1H). 13C NMR (176 MHz, DMSO-d6) δ 177.52,
160.25, 144.62, 137.61, 131.14, 128.77, 125.44, 119.06, 108.93, 87.68, 76.71, 31.92. 13C CPMAS NMR (101
MHz) δ 179.77, 164.39, 145.28, 134.65, 125.47, 111.34, 92.26, 78.21, 33.85. 15N CPMAS NMR (40.556
MHz) δ −217.48, −223.79, −243.05. LC-MS (ESI+) Rt= 1.45 min m/z [M + H]+ = 323.8 HR-MS calculated
for C12H11N3O3Br 323.9984, found 323.9973 (∆= −1.1 mDa). IR (neat): ν (cm−1) = 3000 (NH, w), 2710
(CH, w), 1715 (C=O, s), 1585 (C=N, s), 1445 (s), 1413 (m), 1329 (w), 1169 (m), 1082 (m), 929 (w), 763 (s),
660 (s). Melting point (◦C): 103 ◦C decomposition. Crystal data: C12H10BrN3O3 (M = 324.14 g/mol),
orthorhombic, space group P212121 (no. 19), a = 6.9156(3) Å, b = 13.1025(6) Å, c = 13.3565(6) Å, V =
1210.25(9) Å3, Z = 4, T = 120 K, µ(MoKα) = 3.40 mm−1, Dcalc = 1.779 g/cm3, 32,088 reflections measured
(2Θ ≤ 66.5◦), 4654 unique (Rint = 0.036, Rσ = 0.027), R1 = 0.025 on 4238 reflections with I > 2σ(I), wR2 =
0.058 on all data. CCDC 1986565.
5-Chloro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15d): 1H NMR (599 MHz,
DMSO-d6) δ 10.30 (brs, 1H), 7.22 (dd, J = 8.3, 2.2 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.73 (d, J =
8.3 Hz, 1H), 6.28 (s, 1H), 4.84 (s, 1H), 3.06 (d, J = 14.0 Hz, 1H), 2.90 (d, J = 14.0 Hz, 1H). 13C NMR
(151 MHz, DMSO-d6) δ 178.11, 140.87, 133.20, 128.88, 125.45, 124.48, 110.89, 88.83, 75.08, 24.39. 13C
CPMAS NMR (101 MHz) δ 181.73, 163.08, 146.44, 140.53, 132.67, 128.35, 112.33, 90.37, 76.86, 36.96. 15N
CPMAS NMR (40.556 MHz) −198.84, −211.43, −245.96. LC-MS (ESI+) Rt = 1.07 min m/z [M + H]+ =
280.6 HR-MS calculated for C12H11N3O3Cl 280.0489, found 280.0505 (∆ = 1.6 mDa). IR (neat): ν (cm−1)
= 3173 (NH, w), 2627 (CH, w), 1670 (C=O, m), 1610 (C=N, s), 1480 (m), 1440 (m), 1249 (w), 1192 (w),
973 (w), 817 (w), 758 (s), 615 (s). Melting point (◦C): 140 ◦C decomposition.
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3-Hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)-5-methoxyindolin-2-one (15e): 1H NMR (599 MHz,
DMSO-d6) δ 10.02 (brs, 3H), 6.75 – 6.69 (m, 2H), 6.64 (d, J = 8.2 Hz, 1H), 4.86 (s, 1H), 3.68 (s, 3H), 3.04
(d, J = 14.1 Hz, 1H), 2.87 (d, J = 14.1 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 178.41, 160.48, 154.70,
137.96, 135.13, 132.37, 113.70, 111.30, 109.78, 88.96, 75.27, 55.37, 34.35. 13C CPMAS NMR (101 MHz)
δ 180.57, 162.56, 156.41, 139.29, 133.63, 117.12, 112.15, 93.07, 77.07, 55.43, 34.66. 15N CPMAS NMR
(40.556 MHz) δ −200.09, −221.84, −246.55. LC-MS (ESI+) Rt = 1.04 min m/z [M + H]+ = 276.6. HR-MS
calculated for C13H14N3O4 276.0984, found 276.0980 (∆ = −0.4 mDa). IR (neat): ν (cm−1) = 3064 (NH,
w), 2758 (CH, w), 1714 (C=O, s), 1637 (C=N, s), 1597 (s), 1466 (s), 1233 (m), 1053 (m), 765 (s), 537 (m).
Melting point (◦C): 101 ◦C decomposition.
5-Fluoro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15f): 1H NMR (700 MHz,
DMSO-d6) δ 10.23 (brs, 3H), 7.03 – 6.99 (m, 1H), 6.93 (dd, J = 8.2, 2.7 Hz, 1H), 6.71 (dd, J = 8.5,
4.3 Hz, 1H), 6.29 (s, 1H), 4.86 (s, 1H), 3.05 (d, J = 14.0 Hz, 1H), 2.91 (d, J = 14.0 Hz, 1H). 13C NMR (176
MHz, DMSO-d6) δ 178.43, 160.47 (d, J = 33.2 Hz), 158.56, 157.21, 138.11 (d, J = 1.7 Hz), 137.64, 132.93 (d,
J = 7.6 Hz), 115.30 (d, J = 23.2 Hz), 112.08 (d, J = 24.3 Hz), 110.22 (d, J = 7.9 Hz), 88.88, 75.28, 34.27. 13C
CPMAS NMR (101 MHz) δ 180.04, 163.66, 159.53, 143.98, 138.00, 130.76, 119.82, 111.70, 92.78, 77.29,
35.66. 15N CPMAS NMR (40.556) δ −216.10, −225.14, −242.50. LC-MS (ESI+) Rt = 0.80 min m/z [M +
H]+ = 264.4 HR-MS calculated for C12H11N3O3F 264.0784, found 264.0763 (∆ = −2.1 mDa). IR (neat): ν
(cm−1) = 3250 (NH, w), 2965 (w), 2862 (CH, w), 1708 (C=O, m), 1588 (C=N, m), 1485 (s), 1363 (w), 1187
(m), 1077 (w), 1033 (w), 825 (m), 601 (s). Melting point (◦C): 110 ◦C decomposition.
6-Chloro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15g): 1H NMR (599 MHz,
DMSO-d6) δ 10.31 (brs, 3H), 7.10 (d, J = 7.9 Hz, 1H), 6.98 (dd, J = 7.9, 1.9 Hz, 1H), 6.74 (d, J =
1.9 Hz, 1H), 6.23 (s, 1H), 4.83 (s, 1H), 3.04 (d, J = 14.0 Hz, 1H), 2.90 (d, J = 14.0 Hz, 1H). 13C NMR (151
MHz, DMSO-d6) δ 178.38, 143.52, 133.28, 130.06, 125.78, 121.16, 109.52, 88.84, 74.61, 39.10, 34.19. 13C
CPMAS NMR (101 MHz) δ 180.52, 163.52, 142.20, 136.09, 127.70, 111.70, 92.75, 75.70, 35.04. 15N CPMAS
NMR (40.556 MHz) δ −199.82, −209.90, −242.92. LC-MS (ESI+) Rt = 1.48 min m/z [M + H]+ = 280.6
HR-MS calculated for C12H11N3O3Cl 280.0489, found 280.0498 (∆ = 0.9 mDa). IR (neat): ν (cm−1) =
3147 (NH, w), 2771 (CH, w), 1711 (C=O, s), 1592 (C=N, s), 1482 (m), 1447 (w), 1331 (w), 1068 (m), 917
(w), 738 (w), 593 (w). Melting point (◦C): 120 ◦C decomposition.
7-Chloro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15h): 1H NMR (400 MHz,
DMSO-d6) δ 7.25 (dd, J = 8.1, 1.1 Hz, 1H), 7.07 (dd, J = 7.3, 1.2 Hz, 1H), 6.96 (dd, J = 8.1, 7.4
Hz, 1H), 4.80 (s, 1H), 3.05 (d, J = 14.1 Hz, 1H), 2.92 (d, J = 14.0 Hz, 1H). 13C NMR (101 MHz, DMSO-d6)
δ 178.45, 144.15, 139.69, 133.18, 129.10, 122.95, 122.88, 113.68, 88.71, 75.53, 46.10. 13C CPMAS NMR (101
MHz) δ 180.70, 162.73, 145.14, 139.39, 131.75, 130.50, 123.84, 115.65, 90.98, 77.51, 35.83. 15N CPMAS
NMR (40.556 MHz) −200.62, −216.52, −247.87. LC-MS (ESI+) Rt = 1.33 min m/z [M + H]+ = 280.5
HR-MS calculated for C12H11N3O3Cl 280.0489, found 280.0501 (∆ = 1.2 mDa). IR (neat): ν (cm−1) =
3137 (NH, m), 2752 (CH, w), 1713 (C=O, s), 1620 (C=N, s), 1562 (s), 1474 (m), 1454 (m), 1223 (w), 1171
(m), 1138, (s), 782 (s), 736 (s). Melting point (◦C): 134 ◦C decomposition.
3-Hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)-7-(trifluoromethyl)indolin-2-one (15i): 1H NMR (599
MHz, DMSO-d6) δ 10.00 (brs, 3H), 7.47 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 7.3 Hz, 1H), 7.12 (t, J = 7.7 Hz,
1H), 6.37 (s, 1H), 4.82 (s, 1H), 3.10 (d, J = 14.1 Hz, 1H), 2.93 (d, J = 14.1 Hz, 1H). 13C NMR (151 MHz,
DMSO-d6) δ 178.93, 160.32, 139.45, 137.62, 133.13, 128.23, 125.50 (q, J = 4.4 Hz), 123.95 (q, J = 271.7 Hz),
121.65, 110.50 (q, J = 32.6 Hz), 88.76, 73.66, 34.21. 13C CPMAS NMR (101 MHz) δ 181.20, 163.58, 142.93,
138.75, 132.50, 130.62, 126.20, 122.33, 112.60, 93.37, 72.54, 48.96, 32.16. 15N CPMAS NMR (40.556 MHz)
δ −206.98, −217.10, −246.09. LC-MS (ESI+) Rt = 1.93 min m/z [M + H]+ = 314.3 HR-MS calculated for
C13H11N3O3F3 314.0753, found 314.0758 (∆ = 0.5 mDa). IR (neat): ν (cm−1) = 3175 (NH, s), 2826 (CH,
w), 1734 (C=O, s), 1594 (s), 1455 (s), 1325 (s), 1170 (s), 1119 (s), 1104 (s), 1038 (s), 801 (s), 752 (s), 711 (s),
612 (s). Melting point (◦C): 115 ◦C decomposition.
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7-Fluoro-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15j): 1H NMR (599 MHz,
DMSO-d6) δ 10.42 (brs, 3H), 7.10 (ddd, J = 10.4, 7.9, 1.5 Hz, 1H), 7.02 – 6.83 (m, 2H), 6.30 (brs,
1H), 4.78 (s, 1H), 3.06 (d, J = 14.1 Hz, 1H), 2.93 (d, J = 14.0 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ
178.28, 160.33, 147.03, 145.43, 137.71, 134.26 (d, J = 3.2 Hz), 128.89 (d, J = 12.1 Hz), 122.39 (d, J = 5.6
Hz), 120.36 (d, J = 3.0 Hz), 116.17 (d, J = 17.2 Hz), 88.70, 75.10 (d, J = 2.8 Hz), 34.42. 13C CPMAS NMR
(101 MHz) δ 178.95, 162.17, 148.70, 146.06, 142.92, 132.71, 129.95, 124.18, 119.87, 118.74, 90.85, 76.82,
35.85. 15N CPMAS NMR (40.556) δ −216.39, −223.03, −250.73. LC-MS (ESI+) Rt = 0.77 min m/z [M +
H]+= 264.5. HR-MS calculated for C12H11N3O3F 264.0784, found 264.0764 (∆ = −2.0 mDa). IR (neat):
ν (cm−1)= 3698 (NH, w), 3358 (NH, w), 2974 (CH, s), 1731 (C=O, s), 1647 (w), 1587 (C=N, s), 1557 (s),
1493 (s), 1469 (s), 1332 (w), 1192 (w), 1053 (s), 1033 (s), 1014 (s), 791 (s), 758 (s), 731 (s), 567 (s). Melting
point (◦C): 115 ◦C decomposition.
6-Chloro-2-(2-hydrazinyl-2-oxoethyl)quinoline-4-carbohydrazide (16d): 1H NMR (400 MHz, DMSO-d6) δ
9.97 (s, 1H), 9.38 (s, 1H), 8.17 (d, J = 2.4 Hz, 1H), 8.02 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 9.0, 2.5 Hz, 1H),
7.58 (s, 1H), 4.71 (s, 2H), 4.30 (s, 2H), 3.78 (s, 2H). 13C NMR (101 MHz, DMSO) δ 167.91, 165.43, 157.31,
145.92, 140.34, 131.34, 131.00, 130.42, 124.16, 123.99, 121.03, 43.64. LC-MS (ESI+) Rt = 1.42 min m/z [M +
H]+ = 294.3 HR-MS calculated for C12H13N5O2Cl 294.0758, found 294.0771 (∆ = 1.3 mDa). IR (neat): ν
(cm−1) = 3295 (NH, s), 3274 (NH, s), 3047 (CH, w), 1639 (C=O, s), 1618 (C=O, m), 1587 (C=N, m), 1528
(m), 1373 (m), 1303 (w), 1211 (w), 1013 (m), 1011 (m), 836 (s), 690 (s), 606 (s), 565 (s), 491 (s). Melting
point (◦C): 221 ◦C decomposition.
6-Fluoro-2-(2-hydrazinyl-2-oxoethyl)quinoline-4-carbohydrazide (16f): 1H NMR (700 MHz, DMSO-d6) δ
9.95 (s, 1H), 9.37 (s, 1H), 8.07 (dd, J = 9.3, 5.6 Hz, 1H), 7.86 (dd, J = 10.2, 2.9 Hz, 1H), 7.71 (td, J = 8.8,
2.9 Hz, 1H), 7.58 (s, 0H), 4.55 (brs, 1H), 3.78 (s, 1H). 13C NMR (176 MHz, DMSO-d6) δ 168.00, 165.52,
160.53, 159.14, 156.14, 144.72, 140.54, 131.71, 123.97 (d, J = 10.5 Hz), 120.85, 119.88 (d, J = 25.7 Hz),
108.81 (d, J = 23.6 Hz), 43.53. LC-MS (ESI+) Rt = 0.97 min m/z [M + H]+ = 278.2. HR-MS calculated for
C12H13N5O2F 278.1053, found 278.1035 (∆ = −1.8 mDa). IR (neat): ν (cm−1) = 3275 (NH, s), 3196 (w),
3054 (CH, w), 1643 (C=O, s), 1610 (m), 1533 (s), 1470 (w), 1381 (w), 1227 (w), 1012 (w), 837 (w), 682 (w),
579 (w), 500 (w). Melting point (◦C): 210 ◦C decomposition.
7-Chloro-2-(2-hydrazinyl-2-oxoethyl)quinoline-4-carbohydrazide (16g): 1H NMR (400 MHz, DMSO-d6) δ
9.97 (s, 1H), 9.39 (s, 1H), 8.14 (d, J = 9.0 Hz, 1H), 8.05 (s, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.54 (s, 1H),
4.69 (brs, 2H), 4.31 (brs, 2H), 3.78 (s, 2H). 13C NMR (101 MHz, DMSO) δ 167.93, 165.49, 158.18, 147.92,
141.33, 134.54, 127.48, 121.98, 120.54, 43.68. LC-MS (ESI+) Rt = 1.45 min m/z [M + H]+ = 294.3 HR-MS
calculated for C12H13N5O2Cl 294.0758, found 294.0771 (∆ = 1.3 mDa). IR (neat): ν (cm−1) = 3288.5 (NH,
m), 3250.2 (NH, m), 3074.61 (CH, w), 1713.87 (C=O, s), 1643.3 (C=O, s), 1616.38 (s), 1590.61 (s), 1533.77
(s), 1493.34 (m), 1361.98 (m), 1257.41 (w), 1138.43 (w), 961.82 (m), 839.91 (m), 756.43 (m). Melting point
(◦C): 223 ◦C decomposition.
2-(2-Hydrazinyl-2-oxoethyl)-8-(trifluoromethyl)quinoline-4-carbohydrazide (16i): 1H NMR (599 MHz,
DMSO-d6) δ 9.97 (s, 1H), 9.38 (s, 1H), 8.38 (dd, J = 8.5, 1.4 Hz, 1H), 8.21 (dd, J = 7.5, 1.4 Hz,
1H), 7.76 (dd, J = 8.5, 7.5 Hz, 1H), 7.66 (s, 1H), 4.70 (brs, 1H), 4.30 (brs, 1H), 3.84 (s, 2H). 13C NMR (151
MHz, DMSO-d6) δ 168.18, 165.79, 158.16, 143.93, 142.17, 130.78, 128.95 (q, J = 5.3 Hz), 126.44, 126.23,
124.50 (q, J = 272 Hz), 124.22, 121.36, 44.27. LC-MS (ESI+) Rt = 1.65 min m/z [M + H]+ = 328.3 HR-MS
calculated for C13H13N5O2F3 328.1021, found 328.1028 (∆ = 0.7 mDa). IR (neat): ν (cm−1) = 3295.15 (br,
NH), 1670.75 (m, C=O), 1644.92 (s, C=O), 1596.49 (s), 1530.03 (s), 1363.51 (m), 1297.84 (s), 1162.63 (m),
1130.38 (s), 1051.34 (m), 1005.59 (m), 769.31 (m). Melting point (◦C): 225 ◦C decomposition.
1-Benzyl-3-hydroxy-3-((3-hydroxy-1H-pyrazol-5-yl)methyl)indolin-2-one (15l): 1H NMR (599 MHz,
DMSO-d6) δ 10.97 (brs, 2H), 7.30–7.24 (m, 3H), 7.24–7.20 (m, 1H), 7.17 (td, J = 7.7, 1.3 Hz, 1H),
7.06 – 6.99 (m, 3H), 6.66 (d, J = 7.8 Hz, 1H), 6.37 (s, 1H), 4.90 (d, J = 16.0 Hz, 1H), 4.71 – 4.65 (m, 2H), 3.18
(d, J = 13.9 Hz, 1H), 3.04 (d, J = 13.9 Hz, 1H). 13C NMR (151 MHz, DMSO-d6) δ 176.80, 160.57, 142.55,
137.73, 135.88, 130.69, 129.16, 128.57, 127.11, 126.81, 124.07, 122.25, 108.99, 89.00, 74.93, 42.46, 34.66. 13C
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CPMAS NMR (101 MHz) δ 178.20, 177.34, 164.17, 159.74, 143.92, 141.99, 136.37, 134.72, 131.23, 129.81,
128.03, 126.61, 125.39, 124.44, 123.57, 109.93, 91.69, 90.57, 77.74, 76.23, 44.55, 41.28, 35.56, 34.18. 15N
CPMAS NMR (40.556) δ −134.38, −138.40, −199.90, −202.03, −237.79, −239.63. LC-MS (ESI+) Rt = 1.55
min m/z [M + H]+ = 335.8. HR-MS calculated for C19H18N3O3 336.1348, found 336.1337 (∆ = −1.1
mDa). IR (neat): ν (cm−1) = 3228 (NH, w), 2940 (CH, W), 1699 (C=O, s), 1616 (C=N, s), 1569 (w), 1489
(m), 1469 (s), 1355 (s), 1259 (w), 1179 (m), 1074 (s), 1000 (m), 773 (s), 748 (s), 732 (s), 693 (s). Melting
point (◦C): 166 ◦C decomposition. Crystal data: C19H17N3O3 (M = 335.35 g/mol), monoclinic, space
group P21/n (no. 14), a = 8.5554(6), b = 29.118(2), c = 13.1745(9) Å, β = 92.172(3)◦, V = 3279.6(4) Å3, Z
= 8, T = 120 K, µ(Mo-Kα) = 0.09 mm−1, Dcalc = 1.358 g/cm3, 48,703 reflections measured (2Θ ≤ 50◦),
5792 unique (Rint = 0.067, Rσ = 0.049), R1 = 0.041 on 4146 reflections with I > 2σ(I), wR2 = 0.091 on all
data, CCDC-1986567.
4. Conclusions
We developed a methodology for the synthesis of a new scaffold comprising of two key
pharmacophores units. The procedure is simple and employs readily available hydrazine monohydrate
and other cheap building blocks, such as methyl acetoacetate and isatin. A library of 12 compounds
was prepared in order to study the versatility of the method which appears to be applicable to a range
of isatin starting materials in which the 3-oxo group is active for aldol reactions. Furthermore, we
acquired different spectroscopic analyses such as 15N-MASNMR, 15N-NMR and SXRD to confirm the
structure of the products. To the best our knowledge, no 15N-MASNMR spectra on 3-hydroxypyrazole
scaffolds had previously been performed. The compounds generated are currently under investigation
for specific biological activity and will be reported separately.
Supplementary Materials: The following are available online, 1H and 13C-NMR spectra, 13C and 15N MASNMR
spectra, mass spectra, infrared spectra and XRD crystallographic data of compounds. Crystallographic data
in CIF format have been deposited with Cambridge Structural Database (CCDC-1986565 to 1986567) and are
available online.
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